Apellis Pharmaceuticals
APLS
APLS
300 hedge funds and large institutions have $6.65B invested in Apellis Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 66 funds opening new positions, 105 increasing their positions, 90 reducing their positions, and 45 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
4.86% less ownership
Funds ownership: 98.66% → 93.8% (-4.9%)
5% less capital invested
Capital invested by funds: $7B → $6.65B (-$357M)
11% less funds holding in top 10
Funds holding in top 10: 9 → 8 (-1)
Holders
300
Holding in Top 10
8
Calls
$111M
Puts
$94.7M
Top Buyers
| 1 | +$58.8M | |
| 2 | +$53M | |
| 3 | +$45.4M | |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$44.4M |
| 5 |
ITP
Iron Triangle Partners
Cos Cob,
Connecticut
|
+$32.3M |
Top Sellers
| 1 | -$268M | |
| 2 | -$99.8M | |
| 3 | -$81.5M | |
| 4 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
-$21.3M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$21.3M |